The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Mar. 20, 2018

Filed:

Dec. 10, 2013
Applicants:

Massachusetts Institute of Technology, Cambridge, MA (US);

The Massachusetts General Hospital, Boston, MA (US);

Inventors:

Cliff R. Wong, Cambridge, MA (US);

Moungi G. Bawendi, Cambridge, MA (US);

Dai Fukumura, Newton, MA (US);

Rakesh K. Jain, Wellesley, MA (US);

Assignees:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 9/14 (2006.01); A61K 47/48 (2006.01); A61K 47/62 (2017.01); A61K 47/56 (2017.01); A61K 47/64 (2017.01); A61K 47/55 (2017.01); A61K 47/50 (2017.01);
U.S. Cl.
CPC ...
A61K 47/48915 (2013.01); A61K 47/48338 (2013.01); A61K 47/48892 (2013.01); A61K 47/50 (2017.08); A61K 47/55 (2017.08); A61K 47/56 (2017.08); A61K 47/62 (2017.08); A61K 47/64 (2017.08); A61K 47/641 (2017.08);
Abstract

Nanoparticles for a selective, two stage delivery to tumors have been developed. The nanoparticles are initially sized so that they preferentially accumulate in the tumor tissue as a result of leakage through the defective vascular in the solid tumors. Once in the tumor tissue, the nanoparticles are cleaved hydrolytically and/or by enzymatic cleavage over time to release smaller nanoparticles carrying therapeutic, prophylactic or diagnostic agents into the necrotic interior of the tumors. This provides a simple, elegant and highly effective means of delivery drug selectively not just to tumors generally, but, more importantly, into the poorly vascularized necrotic interiors which drugs are normally unable to penetrate. The nanoparticles have a number of advantages: less toxicity due to selective accumulation only in the tumors; access into the poorly vascularized necrotic interiors of the tumor; and sustained release over a period of time within the tumor.


Find Patent Forward Citations

Loading…